Dexamethasone

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.4. Hormones and antihormones

EMLc ATC codes: H02AB02

Indication	Burkitt lymphoma including Burkitt leukaemia ICD11 code: 2A85.6
INN	Dexamethasone
Medicine type	Chemical agent
List type	Complementary
Formulations	**Oral > Liquid:** 2 mg per 5 mL (as sodium phosphate) (EMLc) **Parenteral > General injections > unspecified:** 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) **Oral > Solid > tablet:** 2 mg (as dexamethasone base) (EMLc) ; 4 mg (as dexamethasone base)
EML status history	First added in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Dexamethasone
DrugBank	Dexamethasone

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.